Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Swiss Med Wkly ; 154: 3732, 2024 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-38749028

RESUMEN

INTRODUCTION: With the emergence of newer SARS-CoV-2 variants and their substantial effects on the levels and duration of protection against infection, an understanding of these characteristics of the protection conferred by humoral and cellular immunity can aid in the proper development and implementation of vaccine and safety guidelines. METHODS: We conducted a rapid literature review and searched five electronic databases weekly from 1 November 2021 to 30 September 2022. Studies that assessed the humoral or cellular immunity conferred by infection, vaccination or a hybrid (combination of both) in adults and risk groups (immunocompromised and older populations) were identified. Studies were eligible when they reported data on immunological assays of COVID-19 (related to vaccination and/or infection) or the effectiveness of protection (related to the effectiveness of vaccination and/or infection). RESULTS: We screened 5103 studies and included 205 studies, of which 70 provided data on the duration of protection against SARS-CoV-2 infection. The duration of protection of adaptive immunity was greatly impacted by Omicron and its subvariants: levels of protection were low by 3-6 months from exposure to infection/vaccination. Although more durable, cellular immunity also showed signs of waning by 6 months. First and second mRNA vaccine booster doses increased the levels of protection against infection and severe disease from Omicron and its subvariants but continued to demonstrate a high degree of waning over time. CONCLUSION: All humoral immunities (infection-acquired, vaccine-acquired and hybrid) waned by 3-6 months. Cellular immunity was more durable but showed signs of waning by 6 months. Hybrid immunity had the highest magnitude of protection against SARS-CoV-2 infection. Boosting may be recommended as early as 3-4 months after the last dose, especially in risk groups.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Inmunidad Celular , SARS-CoV-2 , Humanos , COVID-19/prevención & control , COVID-19/inmunología , SARS-CoV-2/inmunología , Vacunas contra la COVID-19/inmunología , Inmunidad Celular/inmunología , Inmunidad Humoral/inmunología , Inmunización Secundaria , Vacunación
2.
BMC Public Health ; 22(1): 1073, 2022 05 31.
Artículo en Inglés | MEDLINE | ID: mdl-35641949

RESUMEN

Emerging infectious diseases are a growing threat in sub-Saharan African countries, but the human and technical capacity to quickly respond to outbreaks remains limited. Here, we describe the experience and lessons learned from a joint project with the WHO Regional Office for Africa (WHO AFRO) to support the sub-Saharan African COVID-19 response.In June 2020, WHO AFRO contracted a number of consultants to reinforce the COVID-19 response in member states by providing actionable epidemiological analysis. Given the urgency of the situation and the magnitude of work required, we recruited a worldwide network of field experts, academics and students in the areas of public health, data science and social science to support the effort. Most analyses were performed on a merged line list of COVID-19 cases using a reverse engineering model (line listing built using data extracted from national situation reports shared by countries with the Regional Office for Africa as per the IHR (2005) obligations). The data analysis platform The Renku Project ( https://renkulab.io ) provided secure data storage and permitted collaborative coding.Over a period of 6 months, 63 contributors from 32 nations (including 17 African countries) participated in the project. A total of 45 in-depth country-specific epidemiological reports and data quality reports were prepared for 28 countries. Spatial transmission and mortality risk indices were developed for 23 countries. Text and video-based training modules were developed to integrate and mentor new members. The team also began to develop EpiGraph Hub, a web application that automates the generation of reports similar to those we created, and includes more advanced data analyses features (e.g. mathematical models, geospatial analyses) to deliver real-time, actionable results to decision-makers.Within a short period, we implemented a global collaborative approach to health data management and analyses to advance national responses to health emergencies and outbreaks. The interdisciplinary team, the hands-on training and mentoring, and the participation of local researchers were key to the success of this initiative.


Asunto(s)
COVID-19 , África del Sur del Sahara/epidemiología , COVID-19/epidemiología , Brotes de Enfermedades/prevención & control , Humanos , Salud Pública , Recursos Humanos
3.
Int J Infect Dis ; 110: 457-465, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34332088

RESUMEN

INTRODUCTION: Few data on the COVID-19 epidemiological characteristics among the pediatric population in Africa exists. This paper examines the age and sex distribution of the morbidity and mortality rate in children with COVID-19 and compares it to the adult population in 15 Sub-Saharan African countries. METHODS: A merge line listing dataset shared by countries within the Regional Office for Africa was analyzed. Patients diagnosed within 1 March and 1 September 2020 with a confirmed positive RT-PCR test for SARS-CoV-2 were analyzed. Children's data were stratified into three age groups: 0-4 years, 5-11 years, and 12-17 years, while adults were combined. The cumulative incidence of cases, its medians, and 95% confidence intervals were calculated. RESULTS: 9% of the total confirmed cases and 2.4% of the reported deaths were pediatric cases. The 12-17 age group in all 15 countries showed the highest cumulative incidence proportion in children. Adults had a higher case incidence per 100,000 people than children. CONCLUSION: The cases and deaths within the children's population were smaller than the adult population. These differences may reflect biases in COVID-19 testing protocols and reporting implemented by countries, highlighting the need for more extensive investigation and focus on the effects of COVID-19 in children.


Asunto(s)
COVID-19 , Adulto , África del Sur del Sahara/epidemiología , Prueba de COVID-19 , Niño , Preescolar , Humanos , Incidencia , Lactante , Recién Nacido , SARS-CoV-2
4.
Artículo en Inglés | MEDLINE | ID: mdl-33261039

RESUMEN

Since the novel coronavirus outbreak of SARS-CoV-2 from the first cases whereof were reported in Wuhan, China, in December 2019, our globalized world has changed enormously. On the 11th of March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic, and nations around the world have taken drastic measures to reduce transmission of the disease. The situation is similar in Switzerland, a small high-income country in Central Europe, where the first COVID-19 case was registered on the 25th of February 2020. Through literature review as well as correspondence with public health professionals and experts in mathematical modeling, this case study focuses on the outbreak's impact on Switzerland and on the measures this country has implemented thus far. Along with the rapid spread of the virus, the political organization, economy, healthcare system, and characteristics of the country greatly influence the approach taken in facing the crisis. Switzerland appears to be structurally well-prepared, but, according to mathematical modeling predictions, in order to avoid total collapse of healthcare facilities, the measures taken by the Swiss Government need to reduce the virus transmission chain by at least 70%. Fortunately, updated models on April 22nd show evidence that the non-pharmaceutical measures invoked have decreased transmission by an estimated 89%, proving effective management by the federal government and allowing for progressive deconfinement measures.


Asunto(s)
COVID-19/epidemiología , COVID-19/prevención & control , Pandemias , Humanos , Modelos Teóricos , Suiza/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA